New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareEloralintide vs Vialox

Eloralintide vs Vialox

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Eloralintide
Skin & CosmeticAnti-Aging & Longevity
Vialox
Summary
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
Vialox is a synthetic pentapeptide that mimics the activity of conotoxin from cone snails, acting as an antagonist of nicotinic acetylcholine receptors at the neuromuscular junction. Similar to Syn-Ake but derived from cone snail venom biochemistry, it reduces facial muscle contraction to smooth expression wrinkles.
Half-Life
~7 days (estimated, long-acting design)
Not applicable (topical; effect duration hours)
Admin Route
SubQ
Topical
Research
Typical Dose
Under investigation in Phase 1/2 trials
0.005-0.05% in formulation
Frequency
Once weekly
Twice daily
Key Benefits
  • Once-weekly dosing (vs multiple daily injections for pramlintide)
  • Appetite suppression via central amylin receptor activation
  • Reduction in post-meal glucagon secretion
  • Complementary mechanism to GLP-1 agonists for combination therapy
  • Slows gastric emptying for prolonged satiety
  • Potential additive weight loss when combined with GLP-1 agents
  • Reduces dynamic wrinkles from repetitive facial expressions
  • Reversible muscle-relaxing effect without injection
  • Smooths forehead, periorbital, and perioral lines
  • Complementary to collagen-stimulating peptides
  • Well-studied tolerability in cosmetic concentrations
  • Can be combined with Syn-Ake for dual conotoxin/viper venom effect
Side Effects
  • Nausea
  • Vomiting
  • Decreased appetite
  • Injection site reactions
  • +1 more
  • Generally very well-tolerated topically
  • Rare contact sensitivity or mild irritation
  • No clinically significant systemic neuromuscular effects at cosmetic doses
Stacks With